These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25583818)

  • 21. Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer.
    Duong CP; Westwood JA; Berry LJ; Darcy PK; Kershaw MH
    Immunotherapy; 2011 Jan; 3(1):33-48. PubMed ID: 21174556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
    Weibo P; Zhaoming Y
    Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy with gene-modified T cells: limiting side effects provides new challenges.
    Stauss HJ; Morris EC
    Gene Ther; 2013 Nov; 20(11):1029-32. PubMed ID: 23804078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic engineering of T cells in leukemia and lymphoma.
    Kochenderfer JN
    Clin Adv Hematol Oncol; 2014 Mar; 12(3):190-2. PubMed ID: 24927269
    [No Abstract]   [Full Text] [Related]  

  • 25. [Chimeric Antigen Receptor T-cells -  Gene Therapy of the Future for Malignant Diseases?].
    Šmída M
    Klin Onkol; 2015; 28 Suppl 4():4S44-7. PubMed ID: 26647888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment.
    Slaney CY; Wang P; Darcy PK; Kershaw MH
    Cancer Discov; 2018 Aug; 8(8):924-934. PubMed ID: 30012854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TCR diversity - a universal cancer immunotherapy biomarker?
    McNeel DG
    J Immunother Cancer; 2016; 4():69. PubMed ID: 27879971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CAR mechanics: driving T cells into the MUC of cancer.
    Maher J; Wilkie S
    Cancer Res; 2009 Jun; 69(11):4559-62. PubMed ID: 19487277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Development of cancer immunotherapy by next generation multi-targeting CAR-T cells].
    Sakoda Y; Tamada K
    Rinsho Ketsueki; 2014 Jun; 55(6):651-6. PubMed ID: 24975334
    [No Abstract]   [Full Text] [Related]  

  • 30. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.
    Nolan KF; Yun CO; Akamatsu Y; Murphy JC; Leung SO; Beecham EJ; Junghans RP
    Clin Cancer Res; 1999 Dec; 5(12):3928-41. PubMed ID: 10632322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The basics of CAR T design and challenges in immunotherapy of solid tumors - Ovarian cancer as a model.
    Xu X; Qiu J; Sun Y
    Hum Vaccin Immunother; 2017 Jul; 13(7):1548-1555. PubMed ID: 28272967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imaging of T cells expressing chimeric antigen receptors.
    Roszik J; Rabinovich B; Cooper LJ
    Immunotherapy; 2011 Dec; 3(12):1411-4. PubMed ID: 22091674
    [No Abstract]   [Full Text] [Related]  

  • 33. Novel approaches to promote CAR T-cell function in solid tumors.
    Hull CM; Maher J
    Expert Opin Biol Ther; 2019 Aug; 19(8):789-799. PubMed ID: 31038366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Engineering T-cells with antibody-based chimeric receptors for effective cancer therapy.
    Thistlethwaite F; Mansoor W; Gilham DE; Hawkins RE
    Curr Opin Mol Ther; 2005 Feb; 7(1):48-55. PubMed ID: 15732529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CAR T-cell Therapy for Solid Tumors?
    Cancer Discov; 2018 Nov; 8(11):1341. PubMed ID: 30291124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor.
    Henderson MA; Yong CS; Duong CP; Davenport AJ; John LB; Devaud C; Neeson P; Westwood JA; Darcy PK; Kershaw MH
    Immunotherapy; 2013 Jun; 5(6):577-90. PubMed ID: 23725282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer.
    Magee MS; Snook AE
    Discov Med; 2014 Nov; 18(100):265-71. PubMed ID: 25425467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
    Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
    J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. From the guest editor: The rise of CAR therapy: the CD19 paradigm, and beyond. Introduction.
    Sadelain M
    Cancer J; 2014; 20(2):105-6. PubMed ID: 24667953
    [No Abstract]   [Full Text] [Related]  

  • 40. Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy.
    Karlsson H; Lindqvist AC; Fransson M; Paul-Wetterberg G; Nilsson B; Essand M; Nilsson K; Frisk P; Jernberg-Wiklund H; Loskog A
    Cancer Gene Ther; 2013 Jul; 20(7):386-93. PubMed ID: 23788110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.